Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SEYEDEHSAN NAVABI

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1801229109
CMS profile
4221558
Location
MURRIETA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$35,117.11

142 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SEYEDEHSAN NAVABI

NPI 1801229109 · CMS profile ID 4221558

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

MURRIETA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1801229109?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SEYEDEHSAN NAVABI, NPI 1801229109, CMS profile ID 4221558. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801229109?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SEYEDEHSAN NAVABI, NPI 1801229109, CMS profile ID 4221558. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801229109?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SEYEDEHSAN NAVABI, NPI 1801229109, CMS profile ID 4221558, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–142 of 142 matching records. This page contains 42 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1801229109?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

142 matching records · $35,117.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 142 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–142 of 142.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $48.2804/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032345045 CMS
Lilly USA, LLC $53.5004/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032345053 CMS
Lilly USA, LLC $28.1904/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032391141 CMS
Celgene Corporation $23.9404/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015602999 CMS
Celgene Corporation $4.4604/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015603003 CMS
Eli Lilly and Company $68.8804/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032168441 CMS
Janssen Biotech, Inc. $30.0804/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988663591 CMS
Ferring Pharmaceuticals Inc. $26.5304/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044213429 CMS
Evoke Pharma, Inc. $23.9004/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056623415 CMS
Celgene Corporation $6.6703/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015602975 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $24.0303/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057303003 CMS
Eli Lilly and Company $3,750.0003/24/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032391063 CMS
Lilly USA, LLC $100.7503/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032345061 CMS
Eli Lilly and Company $261.8003/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032168423 CMS
Eli Lilly and Company $33.7303/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032168429 CMS
Eli Lilly and Company $41.3303/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032190907 CMS
Eli Lilly and Company $55.1303/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032190913 CMS
Eli Lilly and Company $216.0003/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032190917 CMS
Eli Lilly and Company $291.8003/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032216785 CMS
Eli Lilly and Company $552.7703/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032266847 CMS
Eli Lilly and Company $32.1403/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032300903 CMS
Eli Lilly and Company $22.9503/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032345015 CMS
Eli Lilly and Company $94.7103/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032345023 CMS
Eli Lilly and Company $22.9503/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032391098 CMS
Eli Lilly and Company $32.5003/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032391105 CMS
Eli Lilly and Company $415.9603/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032391113 CMS
Celgene Corporation $14.6103/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015602995 CMS
Regeneron Healthcare Solutions, Inc. $31.5003/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999325733 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.1303/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055508029 CMS
Eli Lilly and Company $261.8003/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032138589 CMS
Eli Lilly and Company $218.8703/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032168419 CMS
Eli Lilly and Company $261.8003/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032266853 CMS
Eli Lilly and Company $7,101.9503/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032300879 CMS
Eli Lilly and Company $598.4303/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032391071 CMS
Eli Lilly and Company $201.2503/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032391091 CMS
Celgene Corporation $22.4503/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015602971 CMS
NESTLE HEALTHCARE NUTRITION INC. $23.8102/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012453183 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $24.8902/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057191503 CMS
Celgene Corporation $6.5502/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015602967 CMS
Lilly USA, LLC $112.3702/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032391155 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.1101/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055508023 CMS
Evoke Pharma, Inc. $16.9501/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056621839 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $13.36 1
PY2021 $1,976.60 5
PY2022 $6,770.68 24
PY2023 $35,117.11 142
PY2024 $91,061.53 148
PY2025 $144,144.19 184

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $187,813.35 10
PY2024 Principal investigator $56,273.59 6
PY2023 Principal investigator $11,570.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

10 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $46,319.35 12/31/2025 Non-covered Recipient Entity
United Medical Doctors
A Study to Determine the Association of Genetic Variants With Peripheral Biomarkers and Colon Tissue Characteristics in Subjects With a Diagnosis of Ulcerative Colitis or Crohn s Disease. No dispute reported 06/30/2026 1232918117
Principal investigator 1 SANOFI US SERVICES INC. $18,028.00 12/08/2025 Non-covered Recipient Entity
United Medical Doctors United Gastroenterologists
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226087050
Principal investigator 1 Eli Lilly and Company $24,190.59 10/28/2025 Non-covered Recipient Entity
UNITED MEDICAL DOCTORS
A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187891070
Principal investigator 1 SANOFI US SERVICES INC. $3,438.00 10/27/2025 Non-covered Recipient Entity
United Medical Doctors United Gastroenterologists
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226087046
Principal investigator 1 SANOFI US SERVICES INC. $4,946.00 09/08/2025 Non-covered Recipient Entity
United Medical Doctors United Gastroenterologists
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226087041
Principal investigator 1 SANOFI US SERVICES INC. $15,299.00 08/25/2025 Non-covered Recipient Entity
United Medical Doctors United Gastroenterologists
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226087044
Principal investigator 1 Merck Sharp & Dohme LLC $5,500.00 06/09/2025 Non-covered Recipient Entity
United Medical Doctors
A Study to Determine the Association of Genetic Variants With Peripheral Biomarkers and Colon Tissue Characteristics in Subjects With a Diagnosis of Ulcerative Colitis or Crohn s Disease. No dispute reported 06/30/2026 1232918115
Principal investigator 1 Eli Lilly and Company $54,972.54 03/26/2025 Non-covered Recipient Entity
UNITED MEDICAL DOCTORS
AN ADAPTIVE, DOSE-RANGING, PHASE 2 STUDY OF ELTREKIBART GIVEN ALONE OR IN COMBINATION WITH MIRIKIZUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1187891896
Principal investigator 1 SANOFI US SERVICES INC. $691.87 03/04/2025 Non-covered Recipient Entity
United Medical Doctors United Gastroenterologists
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226087007
Principal investigator 1 SANOFI US SERVICES INC. $14,428.00 01/13/2025 Non-covered Recipient Entity
United Medical Doctors United Gastroenterologists
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet No dispute reported 06/30/2026 1226087023